Eloxx Pharmaceuticals Inc is a United States-based pharmaceutical company. It is engaged in the primary business of development and licensing of technology to discover and engineer monoclonal antibodies. The company is focused on building and developing a portfolio of therapeutics for the treatment of cancer and immunological diseases. Its product candidates are derived from multiple proprietary technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds, and Chimerasome nanocages.